BRAIN Biotech AG (BNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BRAIN Biotech AG (BNN) has a cash flow conversion efficiency ratio of -2.326x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.28 Million ≈ $-5.01 Million USD) by net assets (€1.84 Million ≈ $2.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BRAIN Biotech AG - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how BRAIN Biotech AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does BRAIN Biotech AG carry for a breakdown of total debt and financial obligations.
BRAIN Biotech AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BRAIN Biotech AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shree Rama Newsprint Limited
NSE:RAMANEWS
|
0.266x |
|
Futuretech II Acquisition Corp
NASDAQ:FTII
|
-3.681x |
|
Ipopema Securities SA
WAR:IPE
|
2.921x |
|
Optipharm.CO.LTD
KQ:153710
|
0.012x |
|
Yesil Yapi Endustrisi AS
IS:YYAPI
|
0.001x |
|
Cineverse Corp.
NASDAQ:CNVS
|
-0.043x |
|
OPPSTAR
KLSE:0275
|
0.029x |
|
Silvano Fashion Group AS
WAR:SFG
|
0.016x |
Annual Cash Flow Conversion Efficiency for BRAIN Biotech AG (2012–2025)
The table below shows the annual cash flow conversion efficiency of BRAIN Biotech AG from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see BNN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | €1.84 Million ≈ $2.15 Million |
€-9.23 Million ≈ $-10.79 Million |
-5.015x | -1843.65% |
| 2024-09-30 | €13.89 Million ≈ $16.23 Million |
€-3.58 Million ≈ $-4.19 Million |
-0.258x | -40.78% |
| 2023-09-30 | €23.01 Million ≈ $26.91 Million |
€-4.22 Million ≈ $-4.93 Million |
-0.183x | -322.69% |
| 2022-09-30 | €34.25 Million ≈ $40.04 Million |
€-1.49 Million ≈ $-1.74 Million |
-0.043x | +53.57% |
| 2021-09-30 | €41.83 Million ≈ $48.90 Million |
€-3.91 Million ≈ $-4.57 Million |
-0.093x | +48.79% |
| 2020-09-30 | €26.14 Million ≈ $30.56 Million |
€-4.77 Million ≈ $-5.57 Million |
-0.182x | +7.80% |
| 2019-09-30 | €17.09 Million ≈ $19.98 Million |
€-3.38 Million ≈ $-3.95 Million |
-0.198x | -11.84% |
| 2018-09-30 | €30.64 Million ≈ $35.82 Million |
€-5.42 Million ≈ $-6.33 Million |
-0.177x | -45.48% |
| 2017-09-30 | €47.36 Million ≈ $55.37 Million |
€-5.76 Million ≈ $-6.73 Million |
-0.122x | +62.31% |
| 2016-09-30 | €26.93 Million ≈ $31.48 Million |
€-8.68 Million ≈ $-10.15 Million |
-0.322x | +54.88% |
| 2015-09-30 | €5.76 Million ≈ $6.73 Million |
€-4.11 Million ≈ $-4.81 Million |
-0.715x | -153.56% |
| 2014-09-30 | €13.85 Million ≈ $16.19 Million |
€-3.90 Million ≈ $-4.56 Million |
-0.282x | -2.26% |
| 2013-09-30 | €17.59 Million ≈ $20.57 Million |
€-4.85 Million ≈ $-5.67 Million |
-0.276x | +43.22% |
| 2012-09-30 | €12.12 Million ≈ $14.17 Million |
€-5.89 Million ≈ $-6.88 Million |
-0.485x | -- |
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of re… Read more